BridgeMD
Compares treatment options for Recurrent Implantation Failure
Official title Comparing FET Guided by ERA Vs Standard Timing in Patients with Recurrent Implantation Failure
ClinicalTrials.gov ID: NCT06762626
What this study is testing
- What it's testing
- The pregnancy rate of in vitro fertilisation (IVF) remains around 35% per transfer. Women who are not pregnant following several embryo transfers are regarded as having recurrent implantation failure (RIF), with one of the causes being the asynchronization of the embryo and endometrium.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 40, women only
You may be able to join if
- Women with recurrent implantation failure
- Women aged \< 40 years
- Body mass index of women between 18.5 (inclusive) and 30 (exclusive) kg/m²
- Women with at least one high quality frozen blastocyst (BB grade or above) and planning to undergo a single blastocyst transfer
- Women who will give written informed consent
You likely can't join if
- Women with recurrent pregnancy loss (3 or more biochemical or spontaneous miscarriages)
- Either partner with known chromosomal abnormalities including balanced translocations
- Women undergoing preimplantation genetic testing
- Women with endometrial thickness \< 7 mm in the IVF cycle
- Women with a confirmed diagnosis of stage III-IV endometriosis or adenomyosis affecting uterine cavity morphology
- Women with a confirmed diagnosis of antiphospholipid syndrome
See the full eligibility criteria
- Women with recurrent implantation failure
- Women aged \< 40 years
- Body mass index of women between 18.5 (inclusive) and 30 (exclusive) kg/m²
- Women with at least one high quality frozen blastocyst (BB grade or above) and planning to undergo a single blastocyst transfer
- Women who will give written informed consent
- Women with recurrent pregnancy loss (3 or more biochemical or spontaneous miscarriages)
- Either partner with known chromosomal abnormalities including balanced translocations
- Women undergoing preimplantation genetic testing
- Women with endometrial thickness \< 7 mm in the IVF cycle
- Women with a confirmed diagnosis of stage III-IV endometriosis or adenomyosis affecting uterine cavity morphology
- Women with a confirmed diagnosis of antiphospholipid syndrome
- Pathologies affecting the uterine cavity, including polyps, submucosal fibroids, intramural fibroids \> 4 cm, or hydrosalpinx
The study team makes the final eligibility decision.
Where it's taking place
- Hong Kong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 40 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hong Kong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.